Stockscreener 앱 받기
11.43
3.22%
-0.43
전일 마감가:
$11.86
열려 있는:
$11.7
하루 거래량:
39,216
Relative Volume:
0.02
시가총액:
$1.28B
수익:
-
순이익/손실:
$-294.51M
주가수익비율:
-3.2107
EPS:
-3.56
순현금흐름:
$-244.42M
1주 성능:
+1.76%
1개월 성능:
+38.63%
6개월 성능:
-59.89%
1년 성능:
-55.99%
1일 변동 폭
$11.40
$11.83
1주일 범위
$11.09
$12.47
52주 변동 폭
$6.36
$47.45
다인 테라 Stock (DYN) Company Profile
명칭
Dyne Therapeutics Inc
전화
(781) 786-8230
주소
1560 TRAPELO ROAD, WALTHAM
DYN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
11.40 | 1.28B | 0 | -294.51M | -244.42M | -3.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.74 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.33 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
654.80 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
269.40 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
250.80 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
다인 테라 Stock (DYN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-12 | 개시 | BMO Capital Markets | Outperform |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-13 | 개시 | Robert W. Baird | Outperform |
| 2024-11-26 | 개시 | RBC Capital Mkts | Outperform |
| 2024-10-24 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-05-21 | 재확인 | Chardan Capital Markets | Buy |
| 2024-04-30 | 개시 | Morgan Stanley | Overweight |
| 2024-02-20 | 개시 | H.C. Wainwright | Buy |
| 2023-02-27 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | 개시 | Oppenheimer | Outperform |
| 2023-01-26 | 개시 | Guggenheim | Buy |
| 2022-07-20 | 개시 | Chardan Capital Markets | Buy |
| 2022-07-12 | 개시 | Raymond James | Outperform |
| 2020-10-12 | 개시 | JP Morgan | Overweight |
| 2020-10-12 | 개시 | Jefferies | Buy |
| 2020-10-12 | 개시 | Piper Sandler | Overweight |
| 2020-10-12 | 개시 | Stifel | Buy |
모두보기
다인 테라 주식(DYN)의 최신 뉴스
Press Release Distribution & PR Platform - ACCESS Newswire
Investors Who Lost Money on Dyne Therapeutics, Inc. Should Contact Levi & Korsinsky About an Ongoing InvestigationDYN - ACCESS Newswire
Is Dyne Therapeutics Inc. (NASDAQ:DYN) the Most Promising Small-Cap Stock According to Analysts? - Insider Monkey
EC grants orphan drug designation to Dyne Therapeutics’ DMD therapy - Yahoo Finance
11 Most Promising Small-Cap Stocks According to Analysts - Insider Monkey
Dyne Therapeutics Gets EU Orphan Drug Status for Duchenne Treatment - marketscreener.com
Dyne Therapeutics stock rises on orphan drug status By Investing.com - Investing.com Canada
Dyne Therapeutics stock rises on orphan drug status - Investing.com
Dyne Therapeutics (DYN) Gains EU Orphan Drug Status for DYNE-251 - GuruFocus
Dyne Therapeutics Receives European Medicines Agency (EMA) Orpha - GuruFocus
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation For DYNE-251 In Duchenne Muscular Dystrophy - marketscreener.com
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy - The Manila Times
Dyne Therapeutics Receives European Medicines Agency (EMA) - GlobeNewswire
Breakthrough DMD Treatment DYNE-251 Wins Crucial EU Orphan Status as Phase 1/2 Trial Shows Promise - Stock Titan
Dyne Therapeutics' Recent Gains Improve Losses On Insider Purchases Worth US$1.06m - simplywall.st
Gene therapy developers rise on comments from FDA's Makary - Seeking Alpha
More C-suite changes at Dyne - BioCentury
Dyne Therapeutics reshapes leadership team ahead of drug launches By Investing.com - Investing.com South Africa
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | DYN Stock News - GuruFocus
Dyne Therapeutics (DYN) Enhances Leadership Team with Key Appoin - GuruFocus
Dyne Therapeutics Announces Chief Business Officer and Chief Sci - GuruFocus
Dyne Therapeutics reshapes leadership team ahead of drug launches - Investing.com
Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments - The Manila Times
Strategic C-Suite Expansion: Dyne Therapeutics Gears Up for Rare Disease Drug Launches - Stock Titan
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Dyne Therapeutics Reveals Strategic Compensation Plan: 330K Stock Options Granted - Stock Titan
Dyne wins new Outperform at BMO on prospects for lead drug - MSN
Insider Purchases Worth US$1.06m See Losses As Dyne Therapeutics Market Value Drops To US$770m - Yahoo
Myotonic Dystrophy Pipeline Analysis and Clinical Trials - openPR.com
Ex-Dyne team members reconvene at Crescent - biocentury.com
RBC Cuts Price Target on Dyne Therapeutics to $36 From $41, Keeps Outperform, Speculative Risk - MarketScreener
FORCE platform boosts muscle function in dystrophic mice - BioWorld MedTech
Oversold Conditions For Dyne Therapeutics - Nasdaq
FORCE platform leads to Duchenne muscular dystrophy mouse model - BioWorld MedTech
Petri Dish: Late-stage cancer trial halt; Dyne names CFO - The Business Journals
BMO maintains Dyne Therapeutics stock with $50 target By Investing.com - Investing.com Canada
MDA 2025: DYNE-101 improves finger function in DM1 clinical trial - Muscular Dystrophy News
Dyne names Editas’ Erick Lucera CFO - BioCentury
JPMorgan Seeks Clarity On Dyne Therapeutics' DYNE-101 Expansion, Regulatory Path - Benzinga
Sector Update: Health Care Stocks Steady Premarket Friday -March 21, 2025 at 09:24 am EDT - Marketscreener.com
JPMorgan cuts Dyne Therapeutics stock target to $17 from $18 By Investing.com - Investing.com Canada
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer - The National Law Review
Dyne Therapeutics Appoints Erick Lucera as Chief Financial Officer - citybiz
Dyne Therapeutics names new CFO ahead of clinical milestones By Investing.com - Investing.com South Africa
Dyne Therapeutics Names Erick Lucera as CFO -March 20, 2025 at 05:36 pm EDT - Marketscreener.com
Dyne Therapeutics Appoints Erick Lucera as CFO - TipRanks
Dyne Therapeutics Announces Appointment of Erick J. Lucera As Chief Financial Officer - Marketscreener.com
다인 테라 (DYN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
다인 테라 주식 (DYN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Scalzo Richard William | SVP, Head of Finance & Admin. |
Mar 11 '25 |
Sale |
11.38 |
1,343 |
15,283 |
122,330 |
| Beskrovnaya Oxana | Chief Scientific Officer |
Mar 11 '25 |
Sale |
11.38 |
2,153 |
24,501 |
195,840 |
0.70%
3.92%
자본화:
|
볼륨(24시간):